Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CT-102
- Development stage
- Discontinued
- Lead developer
- Cura Therapeutics
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Administration
- Topical
01
Overview
CT-102 is an activated platelet supernatant (APST) developed by Curative Technologies for the treatment of chronic, non-healing wounds, specifically diabetic neurotrophic foot ulcers. It is a biologic product derived from homologous platelets that have been stimulated to release their alpha-granule contents. The resulting supernatant contains a complex, synergistic mixture of multiple growth factors and cytokines, including platelet-derived growth factor (PDGF), epidermal growth factor (EGF), transforming growth factor-beta (TGF-beta), platelet-derived angiogenesis factor (PDAF), platelet factor 4 (PF-4), and both acidic and basic fibroblast growth factors (aFGF and bFGF). These factors work together to accelerate the wound-healing cascade by promoting cell proliferation, chemotaxis, and angiogenesis. CT-102 was historically marketed as part of the Procuren wound care system during the 1990s.
- Brand names
- Procuren
- Other names
- activated platelet supernatantAPST
02
Targets
PDGFR (PDGFR family)EGFR (Epidermal growth factor receptor)TGFBR (TGF-beta receptor)FGFR (FGFR family)
Beyond the preview
Go deeper on CT-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CT-102.